Genetic Technologies US$6.56 Million Capital Raising
Filed with ASX · · 2 pages · English
Melbourne, Australia, 22 January 2021:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into conditional agreements with several institutional investors for the purchase and sale in a registered direct offering of of 1,250,000 American Depositary Shares (“ADSs”), each representing
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Genetic Technologies appoints Simon Morriss as CEO
- GTG Secures US and ANZ Distribution Rights for PREDICTIX
- GTG Announces US$5.1 Million Capital Raising
- Response to ASX Early Release of Information Query
- US Patent Office Grants Key Risk Test Patent
Later from Genetic Technologies
- 1H21 Half Year Results
- Pause in Trading
- GTG signs 3-year US licence agreement for COVID risk test
- COVID- 19 Risk Test Approved for Commercial Release
- GTG COVID-19 Risk Test launched in USA
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies